Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

  • Mats Jerkeman
  • P Aman
  • Eva Cavallin-Ståhl
  • E Torlakovic
  • Måns Åkerman
  • Felix Mitelman
  • Thoas Fioretos
Publishing year: 2002
Language: English
Pages: 161-165
Publication/Series: International Journal of Oncology
Volume: 20
Issue: 1
Document type: Journal article
Publisher: D.A. Spandidos

Abstract english

The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.


  • Cancer and Oncology
  • Gene Rearrangement B-Lymphocyte : genetics
  • Human
  • Immunophenotyping
  • Lymphoma B-Cell : drug therapy : genetics
  • Leucovorin : therapeutic use
  • Lactate Dehydrogenase : metabolism
  • Lymphoma Large-Cell Diffuse : drug therapy : genetics
  • Male
  • Methotrexate : therapeutic use
  • Middle Age
  • Neoplasm Staging
  • Prednisone : therapeutic use
  • Prognosis
  • Proto-Oncogene Proteins : genetics
  • Support Non-U.S. Gov't
  • Vincristine : therapeutic use
  • Transcription Factors : genetics
  • Doxorubicin : therapeutic use
  • DNA-Binding Proteins : genetics
  • DNA Neoplasm : analysis : metabolism
  • Cyclophosphamide : therapeutic use
  • Blotting Southern
  • Bleomycin : therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols : therapeutic use
  • Aged
  • Adolescence
  • Adult


  • ISSN: 1019-6439
Thoas Fioretos
E-mail: thoas [dot] fioretos [at] med [dot] lu [dot] se

Research team manager

Translational Genomic and Functional Studies of Leukemia

+46 46 222 45 95

+46 70 334 33 67



Division of Clinical Genetics

+46 46 222 45 95

+46 70 334 33 67